The Agreement on trade aspects of intellectual property rights (TRIPS) is an international agreement between all member states of the World Trade Organization (WTO). It establishes minimum standards for the regulation of different forms of intellectual property (IP) by national governments, as applied to nationals of other WTO member countries.  TRIPS was negotiated at the end of the Uruguay Round of the General Agreement on Tariffs and Trade (GATT) between 1989 and 1990 and is managed by the WTO. In addition to the basic intellectual property standards established by the TRIPS Agreement, many nations have engaged in bilateral agreements to introduce a higher level of protection. This collection of standards, known as TRIPS+ or TRIPS-Plus, can take many forms.  The general objectives of these agreements are as follows: a 2003 agreement relaxed the requirements of the internal market and allows developing countries to export to other countries where there is a national health problem as long as the exported drugs are not part of a commercial or industrial policy.  Drugs exported under such a regime may be packaged or coloured differently to prevent them from harming the markets of industrialized countries. Unlike other intellectual property agreements, TRIPS has an effective enforcement mechanism. States can be disciplined by the WTO dispute settlement mechanism. TRIPS conditions that impose more standards beyond TRIPS were also discussed.  These free trade agreements contain conditions that limit the ability of governments to create competition for generic drug manufacturers.